Taysha Gene Therapies posts TSHA-102 Rett syndrome program update with longer-term REVEAL Phase 1/2 data

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

0.00
  • Taysha highlighted longer-term Phase 1/2 REVEAL Part A data for TSHA-102 in Rett syndrome, supporting a potential BLA based on a 6-month interim analysis.
  • All 12 treated patients ages 6-21 gained or regained at least 1 developmental milestone, exceeding the FDA-aligned 33% minimum threshold.
  • Milestone gains rose 69% from 6 to 12 months, rising 94% from 6 to at least 12 months; follow-up extended to 30 months.
  • Total functional gains reached 310 at at least 12 months, including 31 developmental milestones; average gains per patient increased to 26.
  • No treatment-related serious adverse events or dose-limiting toxicities were reported, with all patients followed for at least 12 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.